CSL Behring

Last updated
CSL Behring LLC
ASX:  CSL
Industry Biopharmaceutical, health care
Headquarters King of Prussia, Pennsylvania
Key people
Paul McKenzie, CEO and Managing Director of CSL Limited
Number of employees
27,000+ [1]
Parent CSL Limited
Website www.cslbehring.com

CSL Behring is a biopharmaceutical company, manufacturing plasma-derived, and recombination therapeutic products. [2] The company is a combination of Behringwerke, founded in 1904 in Marburg, Germany by Emil von Behring, and the Commonwealth Serum Laboratories (CSL), established in Australia in 1916 to provide vaccines to the people of Australia, as well as other companies acquired since 2004.

Contents

About

CSL Behring's parent company, CSL Limited, is headquartered in Melbourne, Victoria, Australia. [3] As part of a global alignment, the CSL Behring brand was established in 2007. Previously known as ZLB Behring, the company's history dates back to 1904 when Behringwerke was founded in Germany by Emil von Behring, winner of the first Nobel Prize in Medicine as the inventor of serum therapy or serology. [4]

CSL Behring operates CSL Plasma, one of the world's largest plasma collection networks. It has over 12,000 employees and more than 270 plasma collection centres covering China, the US, and Europe. [5] [6] [7]

History

In 1904, Von Behring founded the Behringwerke in Marburg, Germany, for experimental work on disease prevention and the manufacture of sera and vaccines. In 1913, Behringwerke expanded to produce a gas gangrene antiserum and a cholera vaccine.

The Commonwealth Serum Laboratories (now CSL Ltd.) were established in Australia in 1916 to provide vaccines to the people of Australia and New Zealand. In 1930, CSL released an antivenom for tiger snake bites. In 1944, CSL began producing penicillin for the military and Australia.

In 1954, Australian CSL officer Val Bazeley assisted Jonas Salk with the production of the experimental polio vaccine used in the first clinical trials in the US. Bazeley returned to Australia to set up production of the Salk vaccine at CSL.

In 1981, Behringwerke introduced Haemate, human plasma coagulation factor VIII/von Willebrand factor complex, for the treatment of patients with Hemophilia A.

In 1991, CSL Limited was incorporated in Australia. The company went private in 1994 and was listed on the Australian Stock Exchange.

In 2007, ZLB Behring became CSL Behring. In 2009, ZLB Plasma changed its name to CSL Plasma to align with its parent company and opened plasma testing laboratories in Knoxville, Tennessee. That same year, the National Organization for Rare Disorders (NORD) recognised CSL Behring for developing and marketing a treatment in the U.S. for acute bleeding episodes in patients with congenital fibrinogen deficiency, and the Swiss government awarded CSL Behring the Tell Award.

In 2012, the European Organisation for Rare Diseases recognised CSL Behring for developing and manufacturing therapies to treat rare and serious medical conditions with a 2012 EURORDIS Company Award. [8]

Sales and acquisitions

Over the past century, CSL Behring has acquired:

In 2000, the company acquired ZLB from the Swiss Red Cross for $525 million. [9] U.S. plasma collector Nabi, which helped form the world's largest plasma collection network in CSL Plasma, was acquired in 2001.

The company sold Animal Health and acquired the U.S. coagulation-therapy maker Aventis Behring in 2004 for $925 million [10] combining it with ZLB Bioplasma to create ZLB Behring (later CSL Behring). The following year the company sold JRH Biosciences, which the company had acquired in 1994.

Zenyth Therapeutics was acquired in 2006.

Calimmune, a leader in gene-modification and cell-delivery technology, [11] was acquired in 2020 for a reported $91 million. [12]

In 2020, CSL Behring picked up a 2017 option agreement and acquired Vitaeris, a biopharmaceutical company focused on the development of Clazakizumab as a potential treatment option for organ transplant recipients experiencing rejection.

In August 2022, the company finalized its purchase of Vifor Pharma for a reported $11.7 billion. [13]

Offices

The company's United States headquarters is in King of Prussia, Pennsylvania. It has 27,000+ employees in 30 countries. Major manufacturing centers are located in Bern, Switzerland;Marburg, Germany; Kankakee, Illinois; and Broadmeadows, Australia. [ citation needed ]

Related Research Articles

<span class="mw-page-title-main">Emil von Behring</span> German physiologist (1854–1917)

Emil von Behring, born Emil Adolf Behring, was a German physiologist who received the 1901 Nobel Prize in Physiology or Medicine, the first one awarded in that field, for his discovery of a diphtheria antitoxin. He was widely known as a "saviour of children", as diphtheria used to be a major cause of child death. His work with the disease, as well as tetanus, has come to bring him most of his fame and acknowledgment. He was honoured with Prussian nobility in 1901, henceforth being known by the surname "von Behring."

This is a timeline of the development of prophylactic human vaccines. Early vaccines may be listed by the first year of development or testing, but later entries usually show the year the vaccine finished trials and became available on the market. Although vaccines exist for the diseases listed below, only smallpox has been eliminated worldwide. The other vaccine-preventable illnesses continue to cause millions of deaths each year. Currently, polio and measles are the targets of active worldwide eradication campaigns.

Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index. In 2023, the company’s seat in Forbes Global 2000 was 89.

<span class="mw-page-title-main">Émile Roux</span> French physician (1853–1933)

Pierre Paul Émile Roux FRS was a French physician, bacteriologist and immunologist. Roux was one of the closest collaborators of Louis Pasteur (1822–1895), a co-founder of the Pasteur Institute, and responsible for the institute's production of the anti-diphtheria serum, the first effective therapy for this disease. Additionally, he investigated cholera, chicken-cholera, rabies, and tuberculosis. Roux is regarded as a founder of the field of immunology.

In immunology, antiserum is a blood serum containing antibodies that is used to spread passive immunity to many diseases via blood donation (plasmapheresis). For example, convalescent serum, passive antibody transfusion from a previous human survivor, used to be the only known effective treatment for ebola infection with a high success rate of 7 out of 8 patients surviving.

<span class="mw-page-title-main">CSL Limited</span> Australian biotechnology company

CSL Limited is an Australian multinational specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions. CSL's product areas include blood plasma derivatives, vaccines, antivenom, and cell culture reagents used in various medical and genetic research and manufacturing applications. The company was established in 1916 as Commonwealth Serum Laboratories and was wholly owned by the Australian federal government until its privatisation in 1994.

<span class="mw-page-title-main">Biocon</span> Indian multinational biopharmaceutical company

Biocon Limited is an Indian biopharmaceutical company based in Bangalore. It was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.

C.H. Boehringer Sohn AG & Co. KG is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer (1861–1939) in Ingelheim am Rhein, Germany. As of 2018, Boehringer Ingelheim is one of the world's largest pharmaceutical companies, and the largest private one. Headquartered in Ingelheim, it operates globally with 146 affiliates and more than 47,700 employees. Unlike most large pharmaceutical companies which are listed, the company is private and fully owned by the Boehringer, Liebrecht and von Baumbach families. The company's key areas of interest are: respiratory diseases, metabolism, immunology, oncology and diseases of the central nervous system. Boehringer Ingelheim is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The corporate logo of Boehringer Ingelheim depicts a stylized rendition of the central section of the imperial palace of Charlemagne.

The pharmaceutical industry in India was valued at an estimated US$42 billion in 2021 and is estimated to reach $130 billion by 2030. India is the world's largest provider of generic medicines by volume, with a 20% share of total global pharmaceutical exports. It is also the largest vaccine supplier in the world by volume, accounting for more than 60% of all vaccines manufactured in the world. Indian pharmaceutical products are exported to various regulated markets including the US, UK, European Union and Canada.

Sanofi Pasteur is the vaccines division of the French multinational pharmaceutical company Sanofi. Sanofi Pasteur is the largest company in the world devoted entirely to vaccines. It is one of four global producers of the yellow fever vaccine.

Prothrombin complex concentrate (PCC), also known as factor IX complex, sold under the brand name Kcentra among others, is a combination medication made up of blood clotting factors II, IX, and X. Some versions also contain factor VII. It is used to treat and prevent bleeding in hemophilia B if pure factor IX is not available. It may also be used for reversal of warfarin therapy. It is given by slow injection into a vein.

Serum Institute of India (SII) is an Indian biotechnology and biopharmaceuticals company, based in Pune. It is the world's largest manufacturer of vaccines. It was founded by Cyrus Poonawalla in 1966 and is a part of Cyrus Poonawalla Group.

<span class="mw-page-title-main">Diphtheria vaccine</span> Vaccine against diphtheria

Diphtheria vaccine is a toxoid vaccine against diphtheria, an illness caused by Corynebacterium diphtheriae. Its use has resulted in a more than 90% decrease in number of cases globally between 1980 and 2000. The first dose is recommended at six weeks of age with two additional doses four weeks apart, after which it is about 95% effective during childhood. Three further doses are recommended during childhood. It is unclear if further doses later in life are needed.

Dade Behring was a company which manufactured testing machinery and supplies for the medical diagnostics industry, based in Deerfield, Illinois and Glasgow, Delaware.

<span class="mw-page-title-main">Biological E. Limited</span> Indian biopharmaceutical company

Biological E Limited is an Indian biotechnology and biopharmaceutical company based in Hyderabad, Telangana. It specialises in the areas of low-cost vaccine production.

Behring may refer to:

Biotechnology in India is a sunrise sector within the Indian economy. Agencies of the Government of India concerned with the biotechnology industry include the Department of Biotechnology and the proposed Biotechnology Regulatory Authority of India. As of 2022, the sector is valued at $80 billion. Biotechnology in India is in a growth phase and the sector is expected to be valued at $150 billion by 2025 and surpass $300 billion in value by 2030.

CSL Vifor is a global specialty pharmaceuticals company in the treatment areas of iron deficiency, dialysis, nephrology & rare disease. It is headquartered in Switzerland and consists of CSL Vifor, Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Sanifit Therapeutics.

<span class="mw-page-title-main">Convalescent plasma</span> Blood plasma from disease survivor

Convalescent plasma is the blood plasma collected from a survivor of an infectious disease. This plasma contains antibodies specific to a pathogen and can be used therapeutically by providing passive immunity when transfusing it to a newly infected patient with the same condition. Convalescent plasma can be transfused as it has been collected or become the source material for hyperimmune serum or anti-pathogen monoclonal antibodies; the latter consists exclusively of IgG, while convalescent plasma also includes IgA and IgM. Collection is typically achieved by apheresis, but in low-to-middle income countries, the treatment can be administered as convalescent whole blood.

<span class="mw-page-title-main">CSL Plasma</span> Plasmapheresis company based in Florida

CSL Plasma is a plasmapheresis company which claims to be one of the largest companies of its kind in the world. It is a subsidiary of CSL Limited, a biotechnology company based in Melbourne, Australia, but has their own headquarters in Boca Raton, Florida. The company employs around 17,000 staff and has over 300 locations in multiple countries. Collected plasma, encouraged through company-sponsored programs such as "Plasma P.A.L.S.", is used for testing or manufacturing plasma-derived therapies and medicine. The company was a finalist in the 2021 and 2022 South Florida Business Journal "Business of the Year Awards". In 2023, the company was made to make settlements in two discrimination lawsuits.

References

  1. De Vane, Natalie (October 29, 2020). "CSL Named as One of the World's Best Employers". www.cslbehring.com. CSL Behring. Archived from the original on 2020-11-28. Retrieved February 22, 2021. Forbes magazine has named global biotechnology leader CSL Limited … to its World's Best Employers 2020 list.
  2. "CSL Behring LLC - Company Profile and News". Bloomberg.com. Retrieved 2023-10-16.
  3. "Articles about CSL Behring". BioSpace. Retrieved 2023-09-27.
  4. Nobel Prize in Physiology or Medicine 1901 - Emil von Behring – Biographical. Elsevier Publishing Company, Amsterdam. 1967. p. 16. Retrieved February 22, 2021 via The Nobel Foundation. … for his work on serum therapy, especially its application against diphtheria …{{cite book}}: |work= ignored (help)
  5. "About CSL Plasma". www.cslplasma.com. CSL Plasma. Archived from the original on 2018-10-30. Retrieved February 22, 2021. … operates one of the world's largest and most sophisticated plasma collection networks, …
  6. "CSL Behring: new approaches against Covid-19". Healthcare Mittelhessen. 2020-08-04. Retrieved 2022-03-27.
  7. "CSL Behring Company Information". Drugs.com. Retrieved 2022-03-27.
  8. "EURORDIS". www.eurordis.org. March 22, 2012. Retrieved January 20, 2020.
  9. "Aventis disposes of Behring unit with $925M sale to Australia's CSL -". www.thepharmaletter.com. Retrieved 2023-10-02.
  10. "Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise". www.spglobal.com. Retrieved 2023-10-02.
  11. C. S. L. Behring (August 28, 2017). "CSL Behring to Acquire Biotech Company Calimmune and its Proprietary Stem Cell Gene Therapy Platform". CSL Behring. Archived from the original on 2017-08-29. Retrieved February 22, 2021 via prnewswire.com. …CSL Behring announced today that it has agreed to acquire Calimmune, Inc., …
  12. "*". In Vivo. Retrieved 2023-10-11.
  13. Kansteiner, Fraiser (2 August 2022). "After delay, CSL's $11.7B deal for Vifor poised to close next week". Fierce Pharma. Retrieved 11 October 2023.